A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Thomas Jefferson University
OHSU Knight Cancer Institute
University of Alabama at Birmingham
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sanofi
Nova Scotia Cancer Centre